[Proton pump inhibitors in acute ulcer bleeding--what is evident?].
Bohle
W
W
Klinik für Allgemeine Innere Medizin, Gastroenterologie, Hepatologie und Infektiologie, Katharinenhospital, Klinikum Stuttgart.
Zoller
W G
WG
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D016099:Endoscopy, Gastrointestinal; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D009853:Omeprazole / Q000627:therapeutic use*; D000077402:Pantoprazole; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy* / Q000601:surgery; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors*; D013454:Sulfoxides / Q000627:therapeutic use*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole
Protonenpumpenhemmer bei der akuten Ulkusblutung--was ist gesichert?